(0)
LONDON, April 10, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a patient case study from the Company s ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2021. Through a comprehensive translational research program, data from Patient T-05 offer insight into the
in vivo dynamics of clonal neoantigen T cells (cNeT) post-dosing and the potential to develop a potency-based release assay. As we move through our Phase I/IIa THETIS and CHIRON clinical programs in metastatic melanoma and advanced non-small cell lung cancer, it is important to quantify and characterize cNeT, the active component in our precision T cell therapy, prior to and after cell infusion, said
Message :
Required fields
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer
DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers
Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States
KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT
IRVINE, Calif., April 10, 2021 (GLOBE NEWSWIRE) Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, presented new data at the American Association for Cancer Research (AACR) Annual Meeting 2021, being held virtually from April 10-15, 2021. The presentations featured studies of Oncocyte’s novel
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share:
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (IND)-enabling data for NC762 at the American Association for Cancer Research (AACR) Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer. The research presented by our team reinforces our confidence that NC762, our third program, is a novel immunomedicine with unique anti-tumor properties. We believe it has the potential to provide benefit in multiple oncology indications, particularly in cancers where high B7-H4 expression has been observed, such as breast, ovarian and lung cancers, said Michael Richman, NextCure s president and chief executive officer. We look forward to advancing NC76
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.